Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Gluz

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Journal of Cellular and Molecular Medicine|October 9, 2025
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast TumoursAntonio Sechi, Jolein Mijnes, Sophia Villwock, et al.
Breast Cancer Research : BCR|March 19, 2021
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrialsMonika Graeser, Simone Schrading, Oleg Gluz, et al.
The Journal of Clinical Investigation|July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-respondersGuokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.
JAMA Network Open|February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialLisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast CancerUlrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.
Cancers|July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- TrialMonika Graeser, Oleg Gluz, Claudia Biehl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP TrialNadia Harbeck, Ulrike A Nitz, Matthias Christgen, et al.
The Lancet. Oncology|May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trialSherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Breast Cancer Research : BCR|February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TNGilda Schmidt, Oleg Gluz, Matthias Christgen, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Journal of Cellular and Molecular Medicine|October 9, 2025
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast TumoursAntonio Sechi, Jolein Mijnes, Sophia Villwock, et al.
Breast Cancer Research : BCR|March 19, 2021
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrialsMonika Graeser, Simone Schrading, Oleg Gluz, et al.
The Journal of Clinical Investigation|July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-respondersGuokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.
JAMA Network Open|February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialLisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast CancerUlrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.
Cancers|July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- TrialMonika Graeser, Oleg Gluz, Claudia Biehl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP TrialNadia Harbeck, Ulrike A Nitz, Matthias Christgen, et al.
The Lancet. Oncology|May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trialSherko Kuemmel, Monika Graeser, Peter Schmid, et al.
Breast Cancer Research : BCR|February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TNGilda Schmidt, Oleg Gluz, Matthias Christgen, et al.
Pageof 10